Current Report Filing (8-k)
October 18 2016 - 1:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 18, 2016
Cynapsus
Therapeutics Inc.
(Exact name of registrant as specified in
its charter)
Canada
|
|
001-37426
|
|
98-1226819
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
828 Richmond Street West,
Toronto, Ontario, Canada
(Address of principal executive offices)
|
M6J 1C9
(Zip Code)
|
Registrant’s telephone number, including
area code:
416-703-2449
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On October 18, 2016, Cynapsus Therapeutics
Inc. issued a press release announcing that it has obtained a final order from the Ontario Superior
Court of Justice approving the previously announced plan of arrangement with Sunovion Pharmaceuticals Inc. (the “Arrangement”)
and that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect
to the Arrangement. The full text of the press release is being furnished as Exhibit 99.1 to this Form 8-K, and shall not be deemed
filed under the United States Securities Exchange Act of 1934, as amended.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
d) Exhibits
The following exhibit is furnished herewith:
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release dated October 18, 2016.
|
SIGNATURES
Pursuant to the requirements of the United
States Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
CYNAPSUS THERAPEUTICS INC.
|
|
|
|
Date: October 18, 2016
|
By:
|
/s/ Andrew Williams
|
|
Name:
|
Andrew Williams
|
|
Title:
|
Chief Operating Officer and
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release dated October 18, 2016.
|
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)
Historical Stock Chart
From Oct 2023 to Oct 2024